Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Cabezon-Gutierrez, L; Custodio-Cabello, S; Palka-Kotlowska, M; Oliveros-Acebes, E; Garcia-Navarro, MJ; Khosravi-Shahi, P.

Seroprevalence of SARS-CoV-2-specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data

CANCER TREATMENT REVIEWS. 2020; 90: Nº de citas: 21 [doi:10.1016/j.ctrv.2020.102102]

Ascierto, PA; Del Vecchio, M; Mandala, M; Gogas, H; Arance, AM; Dalle, S; Cowey, CL; Schenker, M; Grob, JJ; Chiarion-Sileni, V; Marquez-Rodas, I; Butler, MO; Maio, M; Middleton, MR; de la Cruz-Merino, L; Arenberger, P; Atkinson, V; Hill, A; Fecher, LA; Millward, M; Khushalani, NI; Queirolo, P; Lobo, M; de Pril, V; Loffredo, J; Larkin, J; Weber, J.

Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

LANCET ONCOLOGY. 2020; 21(11): 1465-1477 Nº de citas: 414 [doi:10.1016/S1470-2045(20)30494-0]

Litton, JK; Hurvitz, SA; Mina, LA; Rugo, HS; Lee, KH; Goncalves, A; Diab, S; Woodward, N; Goodwin, A; Yerushalmi, R; Roch, H; Im, YH; Eiermann, W; Quek, RGW; Usari, T; Lanzalone, S; Czibere, A; Blum, JL; Martin, M; Ettl, J.

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

ANNALS OF ONCOLOGY. 2020; 31(11): 1526-1535 Nº de citas: 286 [doi:10.1016/j.annonc.2020.08.2098]

Michielin, O; van Akkooi, A; Lorigan, P; Ascierto, PA; Dummer, R; Robert, C; Arance, A; Blank, CU; Sileni, VC; Donia, M; Faries, MB; Gaudy-Marqueste, C; Gogas, H; Grob, JJ; Guckenberger, M; Haanen, J; Hayes, AJ; Hoeller, C; Lebbe, C; Lugowska, I; Mandala, M; Marquez-Rodas, I; Nathan, P; Neyns, B; Bagge, RO; Puig, S; Rutkowski, P; Schilling, B; Sondak, VK; Tawbi, H; Testori, A; Keilholz, U.

ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee

ANNALS OF ONCOLOGY. 2020; 31(11): 1449-1461 Nº de citas: 95 [doi:10.1016/j.annonc.2020.07.005]

Keilholz, U; Ascierto, PA; Dummer, R; Robert, C; Lorigan, P; van Akkooi, A; Arance, A; Blank, CU; Sileni, VC; Donia, M; Faries, MB; Gaudy-Marqueste, C; Gogas, H; Grob, JJ; Guckenberger, M; Haanen, J; Hayes, AJ; Hoeller, C; Lebbe, C; Lugowska, I; Mandala, M; Marquez-Rodas, I; Nathan, P; Neyns, B; Bagge, RO; Puig, S; Rutkowski, P; Schilling, B; Sondak, VK; Tawbi, H; Testori, A; Michielin, O.

ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee

ANNALS OF ONCOLOGY. 2020; 31(11): 1435-1448 Nº de citas: 158 [doi:10.1016/j.annonc.2020.07.004]

Cabezon-Gutierrez, L; Custodio-Cabello, S; Palka-Kotlowska, M; Khosravi-Shahi, P.

High-Dose 8% Capsaicin Patch in Treatment of Chemotherapy-Induced Peripheral Neuropathy. A Systematic Review

JOURNAL OF PAIN AND SYMPTOM MANAGEMENT. 2020; 60(5): 1047 Nº de citas: 8 [doi:10.1016/j.jpainsymman.2020.06.026]

Metro, G; Banna, GL; Signorelli, D; Gili, A; Galetta, D; Galli, G; Economopoulou, P; Roila, F; Friedlaender, A; Camerini, A; Christopoulou, A; Cantale, O; De Toma, A; Pizzutilo, P; Jimenez, B; Collazo-Lorduy, A; Calles, A; Baxevanos, P; Linardou, H; Kosmidis, P; Giannarelli, D; Mountzios, G; Addeo, A.

Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression >= 50%

JOURNAL OF IMMUNOTHERAPY. 2020; 43(9): 299-306 Nº de citas: 24 [doi:10.1097/CJI.0000000000000340]

Martin, M; Garcia-Saenz, JA; Manso, L; Llombart, A; Cassinello, A; Atienza, M; Ringeisen, F; Ciruelos, E.

Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer

Future Oncology. 2020; 16(33): 2763-2778 Nº de citas: 11 [doi:10.2217/fon-2020-0604]

Garcia-Alfonso, P; Garcia-Carbonero, R; Garcia-Foncillas, J; Perez-Segura, P; Salazar, R; Vera, R; Cajal, SRY; Hernandez-Losa, J; Landolfi, S; Musulen, E; Cuatrecasas, M; Navarro, S.

Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology

CLINICAL & TRANSLATIONAL ONCOLOGY. 2020; 22(11): 1976-1991 Nº de citas: 12 [doi:10.1007/s12094-020-02357-z]

Moran, LO; Alfonso, PG; Caballero, IA; Garcia, BM; Anula, VT; Carmena, MD; Alsar, JS; Alonso, NG; Beranek, MB; Jimenez, MM; Martin, AJM.

Incidence of venous thromboembolism in patients with colorectal cancer according to oncogenic status

CLINICAL & TRANSLATIONAL ONCOLOGY. 2020; 22(11): 2026-2031 Nº de citas: 9 [doi:10.1007/s12094-020-02339-1]

Marquez-Rodas, I; Longo, F; Rodriguez-Ruiz, ME; Calles, A; Ponce, S; Jove, M; Rubio-Viqueira, B; Perez-Gracia, JL; Gomez-Rueda, A; Lopez-Tarruella, S; Ponz-Sarvise, M; Alvarez, R; Soria-Rivas, A; de Miguel, E; Ramos-Medina, R; Castanon, E; Gajate, P; Sempere-Ortega, C; Jimenez-Aguilar, E; Aznar, MA; Calvo, A; Lopez-Casas, PP; Martin-Algarra, S; Martin, M; Tersago, D; Quintero, M; Melero, I.

Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors

Science Translational Medicine. 2020; 12(565): Nº de citas: 64 [doi:10.1126/scitranslmed.abb0391]

Lope, V; Guerrero-Zotano, A; Casas, A; Baena-Canada, JM; Bermejo, B; Perez-Gomez, B; Criado-Navarro, I; Antolin, S; Sanchez-Rovira, P; Ramos-Vazquez, M; Anton, A; Castello, A; Garcia-Saenz, JA; Munoz, M; de Juan, A; Andres, R; Llombart-Cussac, A; Hernando, B; Franquesa, RM; Caballero, R; Priego-Capote, F; Martin, M; Pollan, M.

Serum Phospholipids Fatty Acids and Breast Cancer Risk by Pathological Subtype

Nutrients. 2020; 12(10): Nº de citas: 10 [doi:10.3390/nu12103132]

Pollan, M; Casla-Barrio, S; Alfaro, J; Esteban, C; Segui-Palmer, MA; Lucia, A; Martin, M.

Exercise and cancer: a position statement from the Spanish Society of Medical Oncology

CLINICAL & TRANSLATIONAL ONCOLOGY. 2020; 22(10): 1710-1729 Nº de citas: 54 [doi:10.1007/s12094-020-02312-y]

Ciruelos, E; Jerusalem, G; Martin, M; Tjan-Heijnen, VCG; Neven, P; Gavila, J; Montemurro, F; Generali, D; Lang, I; Mart?nez-Serrano, MJ; Perello, MF; Conte, P.

Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population

CLINICAL & TRANSLATIONAL ONCOLOGY. 2020; 22(10): 1857-1866 Nº de citas: 3 [doi:10.1007/s12094-020-02327-5]

Calles, A; Aparicio, MI; Alva, M; Bringas, M; Gutierrez, N; Soto, J; Arregui, M; Tirado, VC; Alvarez, EL; del Monte-Millan, M; Massarrah, T; Galera, M; Alvarez, R; Martin, M.

Outcomes of COVID-19 in Patients With Lung Cancer Treated in a Tertiary Hospital in Madrid

Frontiers in Oncology. 2020; 10: Nº de citas: 31 [doi:10.3389/fonc.2020.01777]

Escudero-Vilaplana, V; Calles, A; Collado-Borrell, R; Marzal-Alfaro, MB; Polanco, C; Garrido, C; Suarez, J; Ortiz, A; Appierto, M; Comellas, M; Lizan, L.

Standardizing Health Outcomes for Lung Cancer. Adaptation of the International Consortium for Health Outcomes Measurement Set to the Spanish Setting

Frontiers in Oncology. 2020; 10: Nº de citas: 8 [doi:10.3389/fonc.2020.01645]

Fernandez-Montes, A; Gravalos, C; Pericay, C; Safont, MJ; Benavides, M; EElez, E; Garcia-Alfonso, P; Garcia-Paredes, B; Carrato, A; Aranda, E.

Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion

CLINICAL COLORECTAL CANCER. 2020; 19(3): 165-177 Nº de citas: 14 [doi:10.1016/j.clcc.2020.04.003]

Nunez-Torres, R; Martin, M; Garcia-Saenz, JA; Rodrigo-Faus, M; del Monte-Millan, M; Tejera-Perez, H; Pita, G; de la Torre-Montero, JC; Pinilla, K; Herraez, B; Peiro-Chova, L; Bermejo, B; Lluch, A; Gonzalez-Neira, A.

Association Between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women With Breast Cancer

JAMA Dermatology. 2020; 156(9): 987-991 Nº de citas: 10 [doi:10.1001/jamadermatol.2020.1867]